Purpose: To evaluate the medium and long term clinical outcome of prostatic arteries embolization (PAE) in 460 patients with benign prostatic hyperplasia (BPH). Materials and Methods: PAE was performed in 460 patients with BPH and moderate to severe lower urinary tract symptoms (LUTS) refractory to medical therapy for at least 6 months between March 2009 and July 2013. PAE was performed with non-spherical polyvinyl alcohol (PVA) particles in 372 patients, 300-to 500-mm tris-acryl microspheres (Embosphere) in 40 patients, 300-to 500-mm spherical PVA particles (Bead Block) in 20 patients and 400-mm Polyzenecoated microspheres (Embozene) in 18 patients. PAE outcomes were evaluated based on International Prostate Symptom Score (IPSS), quality of life (Qol) and International Index Erectile Function (IIEF) questionnaires, prostate volume (PV), prostate specific antigen (PSA), and peak urinary flow rate (Qmax) changes from baseline. Clinical success was considered when there was reduction of the total IPSS score at least 25% and r 15, Qol reduction of at least one point or r 3 and no need of medical therapy or any other treatment.
Purpose: Tumor hypoxia has been shown to correlate with treatment failure and progression to a more aggressive cancer phenotype. Hypoxia resulting from embolization also contributes to chemoresistance after TACE. TH302, a nontoxic prodrug, has been shown to be selectively activated by hypoxia resulting in DNA damage and tumor cell death. The study aim was to evaluate the feasibility, safety and efficacy of hepatic hypoxia-activated intraarterial therapy (HAIAT) in a rabbit model. Materials and Methods: 28 VX2 tumor-bearing rabbits were assigned to 4 intraarterial therapy (IAT) regimens: 1) saline (control group); 2) TH302; 3) doxorubicin-Lipiodol emulsion followed by embolization with 100-300μm beads (conventional, cTACE); or 4) a combination of TH302 and cTACE (TH302-cTACE). Blood work was performed pre-IAT and 24/48 hours, 7/14 days post-IAT. Antitumor efficacy was assessed quantitatively on CT (24h pre-, 7/14 days post-IAT). Pathologic tumor necrosis was quantified by slide-by-slide segmentation. Hypoxic fraction (HF) and compartment (HC) were determined by immunohistochemistry (IHC) and morphometrics of internet for alternative treatment options because they are unwilling to undergo a surgical procedure out of concern for sexual side effects. If at some point in the future, PAE becomes accepted as part of the BPH treatment algorithm, this information could be useful in informing and educating the public about this novel treatment approach. Purpose: To summarize metrics of clinical success and rates of complication after prostatic artery embolization (PAE) for the treatment of benign prostatic hyperplasia (BPH) at 6 month and 12 month follow-up periods using all relevant published data. Materials and Methods: PubMed was searched for publications that included PAE for the treatment of BPH as the subject matter through September 2014. Abstracts, review articles, commentaries and position statements were excluded. Articles that provided original data sets describing the safety and efficacy of PAE for the treatment of BPH written in the English language were included. Because of concern for data being reprinted in multiple papers, only the study with the largest sample size was included from author groups that had more than one study that met the inclusion criteria. Appropriateness for inclusion of each article was determined by two reviewers independently. Data from studies that were included were compiled and summarized using pooled weighted means. Major and minor complications were characterized using the SIR definitions.
Results: The search identified 141 articles of which 6 studies with a total of 467 patients were included. PAEs were performed bilaterally 85.7% (400/467) of the time and unilaterally 12.4% (58/467) of the time with nine patients unable to be embolized. The pooled weighted means of the clinical success metrics were as follows: the International Prostate Symptom Score went from 23.9 to 11.6 at 6 months and to 10.8 at 12 months. Quality of Life scoring went from 4.6 (mostly dissatisfied to unhappy) to 2.2 (mostly satisfied) at 6 months and to 2.0 (mostly satisfied) at 12 months. The total prostate volume decreased by 31.7% at 6 months and by 34.3% at 12 months. The peak urine flow velocity went from 8.36 ml/s to 15.73 ml/s at 6 months and to 16.87 ml/s at 12 months. There were a total of 22 minor complications and 1 major complication resulting in a pooled minor complication rate of 4.7% (22/ 467) and a pooled major complication rate of 0.2% (1/467). Conclusion: PAE is effective in improving lower urinary tract symptoms caused by BPH with a low complication rate across a moderate sized pooled patient population in the short to mid-term. Purpose: Surgical treatment of small or large-volume BPH is associated with high failure rates and complications such as bladder neck strictures and contractures. We present our experience of PAE in varying gland sizes. Materials and Methods: Institutional Review Board approved retrospective study of 78 consecutive PAE patients from January 2011 to July 2014. Patients were evaluated at baseline, 1, 3, and 6 months (m) with American Urological Association (AUA-SI) symptom index including quality of life-related symptoms (QoL), International Index of Erectile Function (IIEF) and prostate imaging (MRI, US or CT at baseline). Analysis was performed for each stratified group (1: o50cc, 2:50-80cc, 3:480 cc) individually from baseline to 1,3, and 6m and between groups at each follow-up to assess for differences in outcome. Results: Baseline volumes were: Group 1 (37.5 cc, 25.9-48, n¼16), 2 (65.7 cc, 52-79.5, n¼26), 3 (139 cc, 80-274, n¼36) . No significant differences in baseline age, AUA score, QoL or IIEF between groups (mean 65.2 yr, 26.4 AUA, 4.9 Qol, 14 IIEF, N¼78). Technical success was achieved in 75/78 (96%), with 2 unilateral embolizations and 1 unsuccessful secondary to bilateral atherosclerotic occlusion. Statistically significant reduction in AUA was achieved in all groups from baseline to 1, 3 and 6m (n¼77) (Group 1: Baseline 27.2 to 12.7, 12.0, 11.2 (po0.006); Group 2: 25.6 to 16.4, 14.8, 14.0 (po0.007); Group 3: 26.7 to 14.6, 14.1, 16.3 (po0.001)), as well as statistically significant improvement in QoL. Comparative analysis demonstrated no statistically significant difference in outcomes between groups 1, 2 and 3 at all intervals. No change in IIEF for all groups was noted. Two minor (Society of Interventional Radiology Complications Classification System) complications occurred: groin hematoma and urinary tract infection. Conclusion: PAE appears to offer similar positive clinical benefits to 6 months in patients with varying gland size. Future study aimed at comparing recurrence rates and procedural differences is warranted.
The preliminary outcome of prostatic arteries embolization with bead block for patients with benign prostatic hyperplasia 27% in 2003 vs 30% in 2013) . Laparoscopic procedural use however increased markedly over the same period (2.55% to 24.75%). The percent of hysterectomy and myomectomy patients on Medicaid remained relatively constant but significantly increased for UFE (.03% % in 2003; 19% in 2013) . Conclusion: Since satisfaction rates for these procedures have been shown to be similar, one may expect uterine-preserving procedures such as laparoscopic myomectomy and UFE to experience similar growth. Despite UFE being a wellestablished alternative, gynecologists are consciously or unconsciously referring more patients with lower-paying insurance (Medicaid) to interventional radiology during the same time there was 400% growth in the number of laparoscopic myomectomy (1300% increase in overall laparoscopic procedures). Although incentives such as financial gains and selfreferral are readily apparent they are rarely discussed in terms of specific examples and solutions. We believe a blend of business and clinical ethics may better encompass the values which motivate medical decisions and allow us to adjust medical education and systems to fit the values we hope to exemplify.
cases, surgery adjunctively to remove the AVM has not been required. Despite previous embolizations with coils, glue, and surgical ligations prior to being referred to our institution, endovascular and direct puncture approaches can successfully manage these lesions. Purpose: Frozen shoulder is a condition of uncertain etiology that is characterized by painful restriction of shoulder motion. Despite the large number of patients affected by this condition, the source of pain in frozen shoulder has not been definitively determined.Neovessels and accompanying nerves are possible sources of pain. Previous work demonstrated that transcatheter arterial embolization for patients with painful tendinopathy resulted in excellent pain relief (1). We hypothesized that abnormal neovessels play an important role in frozen shoulder and that transcatheter arterial embolization can relieve the pain associated with this condition. Materials and Methods: Transcatheter arterial embolization using imipenem/cilastatin sodium as an embolic agent proceeded in eight patients (male, n ¼ 2; mean age 50.3 y)
